https://thepharmadata.com/anthos-therapeutics-highlights-low-bleeding-risk-with-abelacimab-in-azalea-timi-71-af-study/ 2024-09-03T10:10:26+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Anthos-Therapeutics-Highlights-Low-Bleeding-Risk-with-Abelacimab-in-AZALEA-TIMI-71-AF-Study.webp https://thepharmadata.com/arrowhead-pharma-unveils-new-phase-3-data-on-plozasiran-at-esc-2024/ 2024-09-03T10:16:58+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Arrowhead-Pharma-Unveils-New-Phase-3-Data-on-Plozasiran-at-ESC-2024.webp https://thepharmadata.com/daiichi-sankyo-highlights-gaps-in-cardiovascular-healthcare/ 2024-09-03T10:25:36+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Daiichi-Sankyo-Highlights-Gaps-in-Cardiovascular-Healthcare.webp https://thepharmadata.com/sensorion-to-lead-hearing-loss-symposium-at-world-congress-of-audiology-in-paris-september-2024/ 2024-09-03T10:34:18+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Sensorion-to-Lead-Hearing-Loss-Symposium-at-World-Congress-of-Audiology-in-Paris-September-2024.webp https://thepharmadata.com/daiichi-sankyo-highlights-inequalities-and-unmet-needs-in-cardiovascular-care-as-part-of-its-commitment-to-patients/ 2024-09-03T10:40:55+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Daiichi-Sankyo-Highlights-Inequalities-and-Unmet-Needs-in-Cardiovascular-Care-as-Part-of-Its-Commitment-to-Patients.webp https://thepharmadata.com/lilly-and-eva-pharma-partner-to-increase-baricitinib-availability-in-low-and-middle-income-countries/ 2024-09-09T15:08:29+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Lilly-and-EVA-Pharma-Partner-to-Increase-Baricitinib-Availability-in-Low-and-Middle-Income-Countries.webp https://thepharmadata.com/weekly-insulin-efsitora-alfa-matches-daily-insulin-in-a1c-reduction/ 2024-09-09T15:20:33+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Weekly-Insulin-Efsitora-Alfa-Matches-Daily-Insulin-in-A1C-Reduction.webp https://thepharmadata.com/johnson-johnsons-battle-against-medical-counterfeiting/ 2024-09-09T15:30:51+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Johnson-Johnsons-Battle-Against-Medical-Counterfeiting.webp https://thepharmadata.com/infinitamab-deruxtecan-shows-promising-response-in-phase-2-lung-cancer-trial/ 2024-09-09T15:38:13+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Infinitamab-Deruxtecan-Shows-Promising-Response-in-Phase-2-Lung-Cancer-Trial.webp https://thepharmadata.com/roches-fenebrutinib-shows-near-complete-disease-control-in-ms-for-48-weeks/ 2024-09-09T15:48:02+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Roches-Fenebrutinib-Shows-Near-Complete-Disease-Control-in-MS-for-48-Weeks.webp https://thepharmadata.com/astrazeneca-completes-clinical-program-for-breztris-transition-to-eco-friendly-propellant/ 2024-09-09T15:57:00+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/AstraZeneca-Completes-Clinical-Program-for-Breztris-Transition-to-Eco-Friendly-Propellant.webp https://thepharmadata.com/computational-trop2-biomarker-predicts-outcomes-for-datopotamab-deruxtecan-in-tropion-lung01-phase-iii-trial/ 2024-09-09T16:04:38+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Computational-TROP2-Biomarker-Predicts-Outcomes-for-Datopotamab-Deruxtecan-in-TROPION-Lung01-Phase-III-Trial.webp https://thepharmadata.com/ascendis-pharma-and-royalty-pharma-secure-150-million-royalty-financing-deal/ 2024-09-10T10:55:19+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Ascendis-Pharma-and-Royalty-Pharma-Secure-150-Million-Royalty-Financing-Deal.webp https://thepharmadata.com/ascendis-pharma-announces-q2-2024-financial-results/ 2024-09-10T11:30:37+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Ascendis-Pharma-Announces-Q2-2024-Financial-Results.webp https://thepharmadata.com/who-establishes-new-collaborating-centre-for-longitudinal-ageing-and-life-course-studies/ 2024-09-10T11:43:24+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/WHO-Establishes-New-Collaborating-Centre-for-Longitudinal-Ageing-and-Life-Course-Studies.webp https://thepharmadata.com/successful-completion-of-initial-phase-of-polio-campaign-in-gaza/ 2024-09-10T11:51:55+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Successful-Completion-of-Initial-Phase-of-Polio-Campaign-in-Gaza.webp https://thepharmadata.com/jazz-pharmaceuticals-to-showcase-breakthroughs-in-solid-tumor-oncology-research-at-esmo-2024/ 2024-09-10T11:58:20+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Jazz-Pharmaceuticals-to-Showcase-Breakthroughs-in-Solid-Tumor-Oncology-Research-at-ESMO-2024.webp https://thepharmadata.com/engene-announces-q3-2024-financial-results-and-business-update/ 2024-09-11T11:00:12+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/enGene-Announces-Q3-2024-Financial-Results-and-Business-Update.webp https://thepharmadata.com/ncardia-introduces-ready-to-use-assay-panel-for-efficient-therapeutic-candidate-screening-and-selection/ 2024-09-11T10:02:14+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Ncardia-Introduces-Ready-to-Use-Assay-Panel-for-Efficient-Therapeutic-Candidate-Screening-and-Selection.webp https://thepharmadata.com/corflow-therapeutics-secures-e44m-for-microvascular-obstruction-diagnostic-and-drug-delivery-platform/ 2024-09-11T10:10:08+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/CorFlow-Therapeutics-Secures-E44M-for-Microvascular-Obstruction-Diagnostic-and-Drug-Delivery-Platform.webp https://thepharmadata.com/xencor-announces-planned-public-offering-of-common-stock/ 2024-09-11T10:16:22+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Xencor-Announces-Planned-Public-Offering-of-Common-Stock.webp https://thepharmadata.com/novotech-wins-2024-best-practices-award-for-biotech-cro-leadership/ 2024-09-11T10:25:51+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Novotech-Wins-2024-Best-Practices-Award-for-Biotech-CRO-Leadership.webp https://thepharmadata.com/oisin-biotechnologies-unveils-preclinical-data-from-muscle-building-gene-therapy-program-in-cell/ 2024-09-11T10:34:17+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Oisin-Biotechnologies-Unveils-Preclinical-Data-from-Muscle-Building-Gene-Therapy-Program-in-Cell.webp https://thepharmadata.com/weekly-insulin-efsitora-alfa-achieves-comparable-a1c-reduction-to-daily-insulin-in-adults-with-type-1-diabetes/ 2024-09-12T10:03:24+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Weekly-Insulin-Efsitora-Alfa-Achieves-Comparable-A1C-Reduction-to-Daily-Insulin-in-Adults-with-Type-1-Diabetes.webp https://thepharmadata.com/allergan-aesthetics-launches-botox-cosmetic-for-masseter-muscle-prominence-in-adults-in-china/ 2024-09-12T10:19:04+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Allergan-Aesthetics-Launches-BOTOX-Cosmetic-for-Masseter-Muscle-Prominence-in-Adults-in-China.webp https://thepharmadata.com/pfizer-showcases-broad-oncology-portfolio-and-combination-therapies-at-esmo-2024/ 2024-09-12T10:37:09+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Pfizer-Showcases-Broad-Oncology-Portfolio-and-Combination-Therapies-at-ESMO-2024.webp https://thepharmadata.com/sanofi-radiomedix-and-orano-med-sign-licensing-deal-for-radioligand-cancer-therapy/ 2024-09-12T10:45:25+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Sanofi-RadioMedix-and-Orano-Med-Sign-Licensing-Deal-for-Radioligand-Cancer-Therapy.webp https://thepharmadata.com/advancing-the-development-of-next-generation-cancer-therapies/ 2024-09-12T10:56:11+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Advancing-the-Development-of-Next-Generation-Cancer-Therapies.webp https://thepharmadata.com/fda-approves-ebglyss-for-moderate-to-severe-atopic-dermatitis-in-ages-12/ 2024-09-14T10:20:53+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/FDA-Approves-EBGLYSS™-for-Moderate-to-Severe-Atopic-Dermatitis-in-Ages-12.webp https://thepharmadata.com/fda-approves-roches-tecentriq-hybreza-first-subcutaneous-anti-pd-l1-cancer-immunotherapy/ 2024-09-14T10:28:19+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/FDA-Approves-Roches-Tecentriq-Hybreza-First-Subcutaneous-Anti-PD-L1-Cancer-Immunotherapy.webp https://thepharmadata.com/enhertu-shows-strong-efficacy-in-her2-positive-breast-cancer-with-brain-metastases/ 2024-09-14T10:35:19+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Enhertu-Shows-Strong-Efficacy-in-HER2-Positive-Breast-Cancer-with-Brain-Metastases.webp https://thepharmadata.com/japan-approves-csl-and-arcturus-updated-mrna-covid-19-vaccine-for-jn-1-strain/ 2024-09-14T10:42:33+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Japan-Approves-CSL-and-Arcturus-Updated-mRNA-COVID-19-Vaccine-for-JN.1-Strain.webp https://thepharmadata.com/dupixent-approved-in-u-s-as-first-treatment-for-adolescent-crswn/ 2024-09-14T10:52:23+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Dupixent-Approved-in-U.S.-as-First-Treatment-for-Adolescent-CRSwN.webp https://thepharmadata.com/fda-approves-ocrevus-zunovo-first-twice-a-year-10-minute-ms-injection/ 2024-09-14T11:17:44+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/FDA-Approves-Ocrevus-Zunovo™-First-Twice-a-Year-10-Minute-MS-Injection.webp https://thepharmadata.com/tempus-announces-four-abstracts-accepted-for-esmo-2024-congress/ 2024-09-14T13:26:10+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Tempus-Announces-Four-Abstracts-Accepted-for-ESMO-2024-Congress.webp https://thepharmadata.com/novatek-names-dr-yooni-kim-as-executive-president-for-asia-pacific-to-drive-global-growth/ 2024-09-17T10:42:07+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Novatek-Names-Dr.-Yooni-Kim-as-Executive-President-for-Asia-Pacific-to-Drive-Global-Growth.webp https://thepharmadata.com/immunoprecise-antibodies-ipa-announces-q1-fiscal-2025-financial-results-and-key-business-highlights/ 2024-09-17T10:49:11+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/ImmunoPrecise-Antibodies-IPA-Announces-Q1-Fiscal-2025-Financial-Results-and-Key-Business-Highlights.webp https://thepharmadata.com/pharmalegacy-acquires-bts-research-expands-preclinical-services-into-north-america/ 2024-09-17T10:55:22+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/PharmaLegacy-Acquires-BTS-Research-Expands-Preclinical-Services-into-North-America.webp https://thepharmadata.com/cellworks-predicts-parpi-benefits-in-ovarian-pancreatic-prostate-and-triple-negative-breast-cancers/ 2024-09-17T11:03:30+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Cellworks-Predicts-PARPi-Benefits-in-Ovarian-Pancreatic-Prostate-and-Triple-Negative-Breast-Cancers.webp https://thepharmadata.com/massive-bio-unveils-patient-connect-a-global-solution-for-personalizing-access-to-cancer-clinical-trials/ 2024-09-17T11:09:27+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Massive-Bio-Unveils-Patient-Connect-A-Global-Solution-for-Personalizing-Access-to-Cancer-Clinical-Trials.webp https://thepharmadata.com/fda-approves-ocrevus-zunovo-first-10-minute-biannual-injection-for-multiple-sclerosis/ 2024-09-18T10:02:16+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/FDA-Approves-OCREVUS-ZUNOVO-First-10-Minute-Biannual-Injection-for-Multiple-Sclerosis.webp https://thepharmadata.com/fda-approves-novartis-kisqali-for-reducing-early-breast-cancer-recurrence/ 2024-09-18T10:09:30+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/FDA-Approves-Novartis-Kisqali-for-Reducing-Early-Breast-Cancer-Recurrence.webp https://thepharmadata.com/zoetis-unveils-first-ai-powered-cartridge-based-hematology-analyzer/ 2024-09-18T10:17:55+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Zoetis-Unveils-First-AI-Powered-Cartridge-Based-Hematology-Analyzer.webp https://thepharmadata.com/blue-cross-and-blue-shield-of-alabama-partners-with-labcorp-for-improved-outpatient-lab-services/ 2024-09-18T10:35:15+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Blue-Cross-and-Blue-Shield-of-Alabama-Partners-with-Labcorp-for-Improved-Outpatient-Lab-Services.webp https://thepharmadata.com/viatris-reports-early-tender-results-and-announces-increase-in-pending-maximum-tender-offer/ 2024-09-18T10:44:59+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Viatris-Reports-Early-Tender-Results-and-Announces-Increase-in-Pending-Maximum-Tender-Offer.webp https://thepharmadata.com/wedgewood-introduces-compounded-molnupiravir-for-feline-infectious-peritonitis-treatment/ 2024-09-19T10:05:28+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Wedgewood-Introduces-Compounded-Molnupiravir-for-Feline-Infectious-Peritonitis-Treatment.webp https://thepharmadata.com/cd137-antibodies-clinical-trials-market-opportunities-2027-over-80-drugs-in-development/ 2024-09-19T10:15:17+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/CD137-Antibodies-Clinical-Trials-Market-Opportunities-2027-Over-80-Drugs-in-Development.webp https://thepharmadata.com/alzprotect-reports-positive-phase-2a-open-label-extension-results-for-psp/ 2024-09-19T10:24:02+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Alzprotect-Reports-Positive-Phase-2a-Open-Label-Extension-Results-for-PSP.webp https://thepharmadata.com/glycomine-granted-fda-fast-track-designation-for-glm101-in-pmm2-cdg-treatment/ 2024-09-19T10:30:35+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Glycomine-Granted-FDA-Fast-Track-Designation-for-GLM101-in-PMM2-CDG-Treatment.webp https://thepharmadata.com/takeda-pledges-32m-to-five-new-global-csr-partnerships-for-health-impact/ 2024-09-19T10:37:18+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Takeda-Pledges-32M-to-Five-New-Global-CSR-Partnerships-for-Health-Impact.webp https://thepharmadata.com/neuraptive-therapeutic-to-present-ntx-001-phase-2-interim-results-at-2024-assh-meeting/ 2024-09-20T10:04:30+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Neuraptive-Therapeutic-to-Present-NTX-001-Phase-2-Interim-Results-at-2024-ASSH-Meeting.webp https://thepharmadata.com/cybin-announces-corporate-update-and-upcoming-clinical-milestones/ 2024-09-20T10:10:11+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Cybin-Announces-Corporate-Update-and-Upcoming-Clinical-Milestones.webp https://thepharmadata.com/organon-acquires-dermavant-securing-breakthrough-dermatology-treatment-vtama-tapinarof-cream-1/ 2024-09-20T10:17:03+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Organon-Acquires-Dermavant-Securing-Breakthrough-Dermatology-Treatment-VTAMA-Tapinarof-Cream-1.webp https://thepharmadata.com/family-heart-foundation-partners-with-health-systems-to-use-ai-model-for-detecting-genetic-heart-condition/ 2024-09-20T10:25:55+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Family-Heart-Foundation-Partners-with-Health-Systems-to-Use-AI-Model-for-Detecting-Genetic-Heart-Condition.webp https://thepharmadata.com/positive-phase-1-results-for-personalized-vaccine-in-lymphoplasmacytic-lymphoma/ 2024-09-20T10:31:17+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Positive-Phase-1-Results-for-Personalized-Vaccine-in-Lymphoplasmacytic-Lymphoma.webp https://thepharmadata.com/merck-gets-eu-chmp-nod-for-keytruda-in-two-gynecologic-cancers/ 2024-09-21T10:08:21+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Merck-Gets-EU-CHMP-Nod-for-KEYTRUDA-in-Two-Gynecologic-Cancers.webp https://thepharmadata.com/phase-iii-study-confirms-xofluza-significantly-reduces-influenza-virus-transmission/ 2024-09-21T10:15:12+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Phase-III-Study-Confirms-Xofluza-Significantly-Reduces-Influenza-Virus-Transmission.webp https://thepharmadata.com/flumist-receives-approval-for-self-administration-in-the-us/ 2024-09-21T10:21:51+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/FluMist-Receives-Approval-for-Self-Administration-in-the-US.webp https://thepharmadata.com/fasenra-receives-u-s-approval-for-treating-eosinophilic-granulomatosis-with-polyangiitis/ 2024-09-21T10:29:26+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Fasenra-Receives-U.S.-Approval-for-Treating-Eosinophilic-Granulomatosis-with-Polyangiitis.webp https://thepharmadata.com/pfizer-and-biontech-get-favorable-chmp-opinion-for-omicron-kp-2-adjusted-covid-19-vaccine-in-the-eu/ 2024-09-21T12:34:09+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Pfizer-and-BioNTech-Get-Favorable-CHMP-Opinion-for-Omicron-KP.2-Adjusted-COVID-19-Vaccine-in-the-EU.webp https://thepharmadata.com/us-approves-sarclisa-as-first-anti-cd38-therapy-for-non-transplant-multiple-myeloma-patients/ 2024-09-21T12:41:48+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/US-Approves-Sarclisa-as-First-Anti-CD38-Therapy-for-Non-Transplant-Multiple-Myeloma-Patients.webp https://thepharmadata.com/positive-chmp-opinion-granted-to-samsung-bioepis-and-biogen-for-aflibercept-biosimilar-opuviz/ 2024-09-21T12:54:47+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Positive-CHMP-Opinion-Granted-to-Samsung-Bioepis-and-Biogen-for-Aflibercept-Biosimilar-OPUVIZ.webp https://thepharmadata.com/elanco-launches-fda-approved-zenrelia-for-canine-dermatology/ 2024-09-23T10:13:25+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Elanco-Launches-FDA-Approved-Zenrelia-for-Canine-Dermatology.webp https://thepharmadata.com/governments-advance-pandemic-agreement-for-future-emergency-preparedness/ 2024-09-23T10:22:11+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Governments-Advance-Pandemic-Agreement-for-Future-Emergency-Preparedness.webp https://thepharmadata.com/ipsens-iqirvo-approved-in-eu-as-first-new-treatment-for-pbc-in-a-decade/ 2024-09-23T10:38:23+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Ipsens-Iqirvo-Approved-in-EU-as-First-New-Treatment-for-PBC-in-a-Decade.webp https://thepharmadata.com/pfizer-biontech-get-chmp-approval-for-omicron-kp-2-adapted-vaccine-in-eu/ 2024-09-23T10:50:22+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Pfizer-BioNTech-Get-CHMP-Approval-for-Omicron-KP.2-Adapted-Vaccine-in-EU.webp https://thepharmadata.com/pearsanta-partners-with-evofem-for-u-s-endometriosis-diagnostic-launch-in-mid-2025/ 2024-09-23T10:57:13+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Pearsanta-Partners-with-Evofem-for-U.S.-Endometriosis-Diagnostic-Launch-in-Mid-2025.webp https://thepharmadata.com/who-endorses-cintec-plus-test-highlighting-roches-role-in-cervical-cancer-care/ 2024-09-24T10:02:03+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/WHO-Endorses-CINtec-PLUS-Test-Highlighting-Roches-Role-in-Cervical-Cancer-Care.webp https://thepharmadata.com/catherine-owen-adams-appointed-ceo-of-acadia-pharmaceuticals-succeeding-steve-davis/ 2024-09-24T10:18:10+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Catherine-Owen-Adams-Appointed-CEO-of-Acadia-Pharmaceuticals-Succeeding-Steve-Davis.webp https://thepharmadata.com/gensight-biologics-announces-interim-financial-results-for-h1-2024-and-shares-business-updates/ 2024-09-24T10:25:31+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/GenSight-Biologics-Announces-Interim-Financial-Results-for-H1-2024-and-Shares-Business-Updates.webp https://thepharmadata.com/lantern-pharma-receives-fda-rare-pediatric-disease-designations-for-lp-184-in-ultra-rare-childrens-cancers/ 2024-09-24T10:34:31+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/pexels-tara-winstead-7723558.webp https://thepharmadata.com/imprimed-launches-ai-cancer-treatment-prediction-at-eha-sfpm-expands-precision-medicine-to-humans/ 2024-09-24T10:42:59+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/ImpriMed-Launches-AI-Cancer-Treatment-Prediction-at-EHA-SfPM-Expands-Precision-Medicine-to-Humans.webp https://thepharmadata.com/arrowhead-pharmaceuticals-seeks-clearance-for-phase-1-2a-study-of-aro-inhbe-in-obesity-treatment/ 2024-09-24T10:48:47+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Arrowhead-Pharmaceuticals-Seeks-Clearance-for-Phase-12a-Study-of-ARO-INHBE-in-Obesity-Treatment.webp https://thepharmadata.com/lillys-kisunla-donanemab-azbt-receives-approval-in-japan-for-treating-early-symptomatic-alzheimers-disease/ 2024-09-25T10:12:04+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Lillys-Kisunla-donanemab-azbt-Receives-Approval-in-Japan-for-Treating-Early-Symptomatic-Alzheimers-Disease.webp https://thepharmadata.com/empowering-women-entrepreneurs-2024-botox-cosmetic-grant-launches-crowdfunding/ 2024-09-25T10:50:46+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Empowering-Women-Entrepreneurs-2024-BOTOX-Cosmetic-Grant-Launches-Crowdfunding-2.webp https://thepharmadata.com/roche-unveils-first-test-with-tags-tech-for-detecting-12-respiratory-viruses/ 2024-09-25T10:33:49+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Roche-Unveils-First-Test-with-TAGS-Tech-for-Detecting-12-Respiratory-Viruses.webp https://thepharmadata.com/rituxan-approved-for-steroid-resistant-nephrotic-syndrome/ 2024-09-25T10:47:42+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Rituxan-Approved-for-Steroid-Resistant-Nephrotic-Syndrome.webp https://thepharmadata.com/takeda-gets-approval-for-fruzaqla-in-japan-for-advanced-colorectal-cancer/ 2024-09-25T10:56:39+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Takeda-Gets-Approval-for-FRUZAQLA-in-Japan-for-Advanced-Colorectal-Cancer.webp https://thepharmadata.com/medidata-strengthens-focus-on-patient-experience-with-launch-of-patient-payments/ 2024-09-26T10:16:51+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Medidata-Strengthens-Focus-on-Patient-Experience-with-Launch-of-Patient-Payments.webp https://thepharmadata.com/omnicell-names-nnamdi-njoku-as-executive-vice-president-and-chief-operating-officer/ 2024-09-26T10:25:54+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Omnicell-Names-Nnamdi-Njoku-as-Executive-Vice-President-and-Chief-Operating-Officer.webp https://thepharmadata.com/fujirebio-files-fda-submission-for-alzheimers-plasma-diagnostic-test/ 2024-09-26T10:32:47+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Fujirebio-Files-FDA-Submission-for-Alzheimers-Plasma-Diagnostic-Test.webp https://thepharmadata.com/nashville-expansion-announced-by-harrow/ 2024-09-26T10:38:40+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Nashville-Expansion-Announced-by-Harrow.webp https://thepharmadata.com/bc-patients-neglected-as-province-falls-short-on-essential-medication-coverage/ 2024-09-26T10:43:43+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/BC-Patients-Neglected-as-Province-Falls-Short-on-Essential-Medication-Coverage.webp https://thepharmadata.com/new-study-assesses-awareness-of-high-breast-density-as-a-breast-cancer-risk-factor/ 2024-09-26T10:50:44+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/New-Study-Assesses-Awareness-of-High-Breast-Density-as-a-Breast-Cancer-Risk-Factor.webp https://thepharmadata.com/fda-approves-bristol-myers-squibbs-cobenfy-for-adult-schizophrenia-treatment/ 2024-09-27T10:01:35+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/FDA-Approves-Bristol-Myers-Squibbs-COBENFY-for-Adult-Schizophrenia-Treatment.webp https://thepharmadata.com/beigene-updates-on-fda-advisory-vote-for-pd-1-inhibitors-including-tevimbra-in-escc-and-gastric-gej-cancers/ 2024-09-27T10:11:53+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/BeiGene-Updates-on-FDA-Advisory-Vote-for-PD-1-Inhibitors-Including-TEVIMBRA-in-ESCC-and-GastricGEJ-Cancers.webp https://thepharmadata.com/phare-bio-secures-up-to-27m-from-arpa-h-for-ai-driven-antibiotic-development/ 2024-09-27T10:22:23+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Phare-Bio-Secures-Up-to-27M-from-ARPA-H-for-AI-Driven-Antibiotic-Development.webp https://thepharmadata.com/eclinical-solutions-pioneers-the-future-of-drug-development-at-engage-2024-conference/ 2024-09-27T10:28:55+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/eClinical-Solutions-Pioneers-the-Future-of-Drug-Development-at-ENGAGE-2024-Conference.webp https://thepharmadata.com/bioalberta-and-axialbridge-partner-to-help-alberta-life-sciences-companies-expand-into-the-uk/ 2024-09-27T10:33:28+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/BioAlberta-and-AxialBridge-Partner-to-Help-Alberta-Life-Sciences-Companies-Expand-into-the-UK.webp https://thepharmadata.com/merck-updates-on-phase-3-trial-of-favezelimab-pembrolizumab-combo-in-colorectal-cancer/ 2024-09-28T10:05:15+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Merck-Updates-on-Phase-3-Trial-of-Favezelimab-Pembrolizumab-Combo-in-Colorectal-Cancer.webp https://thepharmadata.com/roches-gazyva-shows-superior-phase-iii-results-in-lupus-nephritis-treatment/ 2024-09-28T10:10:20+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Roches-Gazyva-Shows-Superior-Phase-III-Results-in-Lupus-Nephritis-Treatment-2.webp https://thepharmadata.com/tagrisso-receives-u-s-approval-for-unresectable-stage-iii-egfr-mutated-lung-cancer-patients/ 2024-09-28T10:15:44+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Tagrisso-Receives-U.S.-Approval-for-Unresectable-Stage-III-EGFR-Mutated-Lung-Cancer-Patients.webp https://thepharmadata.com/fda-approves-dupixent-as-the-first-biologic-treatment-for-copd-in-the-u-s/ 2024-09-28T10:22:01+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/FDA-Approves-Dupixent-as-the-First-Biologic-Treatment-for-COPD-in-the-U.S.webp https://thepharmadata.com/fda-approves-bristol-myers-squibbs-cobenfy-for-adult-schizophrenia/ 2024-09-28T10:35:59+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/FDA-Approves-Bristol-Myers-Squibbs-COBENFY-for-Adult-Schizophrenia.webp https://thepharmadata.com/dupixent-dupilumab-becomes-the-first-biologic-treatment-approved-in-the-u-s-for-copd-patients/ 2024-09-28T10:43:14+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Dupixent-dupilumab-Becomes-the-First-Biologic-Treatment-Approved-in-the-U.S.-for-COPD-Patients.webp https://thepharmadata.com/artera-to-present-mmai-platform-insights-for-oligometastatic-prostate-cancer-at-astro-2024/ 2024-09-28T10:57:54+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Artera-to-Present-MMAI-Platform-Insights-for-Oligometastatic-Prostate-Cancer-at-ASTRO-2024.webp https://thepharmadata.com/ge-healthcare-gets-fda-approval-for-flyrcado-pet-radiotracer-to-improve-coronary-artery-disease-diagnosis/ 2024-09-28T11:08:05+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/GE-HealthCare-Gets-FDA-Approval-for-Flyrcado-PET-Radiotracer-to-Improve-Coronary-Artery-Disease-Diagnosis.webp https://thepharmadata.com/odyssey-therapeutics-announces-formation-of-scientific-advisory-board/ 2024-09-28T11:17:31+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Odyssey-Therapeutics-Announces-Formation-of-Scientific-Advisory-Board.webp https://thepharmadata.com/fda-approves-karxt-a-puretech-invented-treatment-for-schizophrenia-in-adults/ 2024-09-28T11:28:59+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/FDA-Approves-KarXT-a-PureTech-Invented-Treatment-for-Schizophrenia-in-Adults.webp https://thepharmadata.com/lupin-partners-with-celnova-to-distribute-orphan-drug-namuscla/ 2024-09-28T11:45:41+05:30 https://thepharmadata.com/wp-content/uploads/2024/09/Lupin-Partners-with-Celnova-to-Distribute-Orphan-Drug-NaMuscla.webp https://thepharmadata.com/sunlink-health-systems-inc-reports-fiscal-2024-q4-and-annual-financial-results/ 2024-10-01T10:06:37+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/SunLink-Health-Systems-Inc.-Reports-Fiscal-2024-Q4-and-Annual-Financial-Results.webp https://thepharmadata.com/repare-therapeutics-presents-phase-1-data-on-camonsertib-with-radiotherapy-at-astro/ 2024-10-01T10:12:51+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Repare-Therapeutics-Presents-Phase-1-Data-on-Camonsertib-with-Radiotherapy-at-ASTRO.webp https://thepharmadata.com/fda-grants-approval-to-fresenius-kabi-and-formycon-for-biosimilar-otulfi-ustekinumab-aauz/ 2024-10-01T10:17:39+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/FDA-Grants-Approval-to-Fresenius-Kabi-and-Formycon-for-Biosimilar-Otulfi-ustekinumab-aauz.webp https://thepharmadata.com/pbirx-expands-leadership-team-to-support-rapid-client-and-account-growth/ 2024-10-01T10:22:59+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/PBIRx-Expands-Leadership-Team-to-Support-Rapid-Client-and-Account-Growth.webp https://thepharmadata.com/2024-antibody-drugs-market-tech-report-leading-companies-profiled-roche-jj-abbvie-merck-amgen/ 2024-10-01T10:28:32+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/2024-Antibody-Drugs-Market-Tech-Report-Leading-Companies-Profiled-Roche-JJ-AbbVie-Merck-Amgen.webp https://thepharmadata.com/immunotek-commemorates-international-plasma-awareness-week/ 2024-10-01T10:34:03+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/ImmunoTek-Commemorates-International-Plasma-Awareness-Week.webp https://thepharmadata.com/arcus-biosciences-to-trial-casdatifan-and-volrustomig-combo-in-renal-cancer/ 2024-10-03T10:15:11+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Arcus-Biosciences-to-Trial-Casdatifan-and-Volrustomig-Combo-in-Renal-Cancer.webp https://thepharmadata.com/immunoprecise-subsidiary-enters-material-transfer-agreement-with-biotheus/ 2024-10-03T10:25:55+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/ImmunoPrecise-Subsidiary-Enters-Material-Transfer-Agreement-with-Biotheus.webp https://thepharmadata.com/forge-biologics-launches-fuel-aav-manufacturing-platform-for-efficient-gene-therapy-production/ 2024-10-03T10:37:48+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Forge-Biologics-Launches-FUEL-AAV-Manufacturing-Platform-for-Efficient-Gene-Therapy-Production.webp https://thepharmadata.com/pharmajet-announces-dr-wouter-latour-as-the-new-chief-executive-officer/ 2024-10-04T10:56:22+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/PharmaJet-Announces-Dr.-Wouter-Latour-as-the-New-Chief-Executive-Officer.webp https://thepharmadata.com/aivita-biomedical-partners-with-levellis-to-license-innovative-skincare-formulations/ 2024-10-03T11:00:49+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/AIVITA-Biomedical-Partners-with-LevEllis-to-License-Innovative-Skincare-Formulations.webp https://thepharmadata.com/lilly-unveils-4-5b-medicine-foundry-for-drug-innovation-and-clinical-trials/ 2024-10-04T10:07:22+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Lilly-Unveils-4.5B-Medicine-Foundry-for-Drug-Innovation-and-Clinical-Trials.webp https://thepharmadata.com/calquence-receives-priority-review-in-the-u-s-for-newly-diagnosed-mantle-cell-lymphoma-patients/ 2024-10-04T10:20:20+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Calquence-Receives-Priority-Review-in-the-U.S.-for-Newly-Diagnosed-Mantle-Cell-Lymphoma-Patients.webp https://thepharmadata.com/enhertu-receives-priority-review-in-the-us-for-her2-low-ultralow-metastatic-breast-cancer-post-endocrine-therapy/ 2024-10-04T10:28:11+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Enhertu-Receives-Priority-Review-in-the-US-for-HER2-LowUltralow-Metastatic-Breast-Cancer-Post-Endocrine-Therapy.webp https://thepharmadata.com/la-la-anthony-teams-up-with-amgen-to-share-how-plaque-psoriasis-impacts-her-life/ 2024-10-04T10:36:10+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/La-La-Anthony-Teams-Up-with-Amgen-to-Share-How-Plaque-Psoriasis-Impacts-Her-Life.webp https://thepharmadata.com/fda-approves-opdivo-with-chemotherapy-for-resectable-nsclc-treatment/ 2024-10-04T10:42:14+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/FDA-Approves-Opdivo-with-Chemotherapy-for-Resectable-NSCLC-Treatment.webp https://thepharmadata.com/gilead-partners-with-six-generics-for-royalty-free-licensing-of-lenacapavir-in-high-incidence-hiv-regions/ 2024-10-04T10:54:03+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Gilead-Partners-with-Six-Generics-for-Royalty-Free-Licensing-of-Lenacapavir-in-High-Incidence-HIV-Regions.webp https://thepharmadata.com/allergan-aesthetics-girls-inc-mark-6-years-urge-pledge-for-stem-mentorship/ 2024-10-05T10:36:30+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Allergan-Aesthetics-Girls-Inc.-Mark-6-Years-Urge-Pledge-for-STEM-Mentorship.webp https://thepharmadata.com/announcement-of-sales-partnership-agreement-with-nxera-pharma-japan-for-insomnia-treatment-quviviq/ 2024-10-05T10:52:47+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Announcement-of-Sales-Partnership-Agreement-with-Nxera-Pharma-Japan-for-Insomnia-Treatment-QUVIVIQ.webp https://thepharmadata.com/teva-and-mabxience-strengthen-partnership-with-new-oncology-biosimilar-candidate/ 2024-10-05T11:03:58+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Teva-and-mAbxience-Strengthen-Partnership-with-New-Oncology-Biosimilar-Candidate.webp https://thepharmadata.com/gigagen-secures-u-s-barda-contract-to-develop-antibody-therapies-for-botulinum-neurotoxins-and-biothreats/ 2024-10-05T11:14:37+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/GigaGen-Secures-U.S.-BARDA-Contract-to-Develop-Antibody-Therapies-for-Botulinum-Neurotoxins-and-Biothreats.webp https://thepharmadata.com/halozyme-expands-global-collaboration-and-licensing-agreement-with-argenx-for-enhanze/ 2024-10-05T11:28:08+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Halozyme-Expands-Global-Collaboration-and-Licensing-Agreement-with-Argenx-for-ENHANZE.webp https://thepharmadata.com/marshall-b-ketchum-university-hosts-second-annual-alumni-homecoming-awards/ 2024-10-05T11:36:53+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Marshall-B.-Ketchum-University-Hosts-Second-Annual-Alumni-Homecoming-Awards.webp https://thepharmadata.com/fda-approves-neoadjuvant-opdivo-and-chemotherapy-for-resectable-non-small-cell-lung-cancer/ 2024-10-05T11:49:23+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/FDA-Approves-Neoadjuvant-Opdivo-and-Chemotherapy-for-Resectable-Non-Small-Cell-Lung-Cancer.webp https://thepharmadata.com/ahf-urges-wider-availability-of-lenacapavir-for-global-hiv-treatment/ 2024-10-05T11:57:12+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/AHF-Urges-Wider-Availability-of-Lenacapavir-for-Global-HIV-Treatment.webp https://thepharmadata.com/fda-approves-cobenfy-how-segal-trials-are-transforming-schizophrenia-treatment/ 2024-10-05T12:02:27+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/FDA-Approves-COBENFY-How-Segal-Trials-are-Transforming-Schizophrenia-Treatment.webp https://thepharmadata.com/mercks-keytruda-achieves-efs-success-in-perioperative-treatment-for-head-and-neck-cancer/ 2024-10-14T10:37:59+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Mercks-KEYTRUDA-Achieves-EFS-Success-in-Perioperative-Treatment-for-Head-and-Neck-Cancer.webp https://thepharmadata.com/merck-to-present-new-data-on-vaccines-and-infectious-disease-at-idweek-2024/ 2024-10-14T10:44:14+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Merck-to-Present-New-Data-on-Vaccines-and-Infectious-Disease-at-IDWeek-2024.webp https://thepharmadata.com/fda-approves-roches-itovebi-for-advanced-breast-cancer-with-pik3ca-mutation/ 2024-10-14T10:50:14+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/FDA-Approves-Roches-Itovebi-for-Advanced-Breast-Cancer-with-PIK3CA-Mutation.webp https://thepharmadata.com/most-children-with-sma-treated-with-evrysdi-achieve-motor-milestones-two-year-data-shows/ 2024-10-14T10:58:01+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Most-Children-with-SMA-Treated-with-Evrysdi-Achieve-Motor-Milestones-Two-Year-Data-Shows.webp https://thepharmadata.com/airsupra-reduces-risk-of-severe-asthma-exacerbations-in-phase-iii-batura-trial/ 2024-10-14T11:04:05+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Airsupra-Reduces-Risk-of-Severe-Asthma-Exacerbations-in-Phase-III-BATURA-Trial.webp https://thepharmadata.com/fda-approves-pfizers-hympavzi-for-hemophilia-a-and-b-treatment/ 2024-10-14T11:17:17+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/FDA-Approves-Pfizers-HYMPAVZI-for-Hemophilia-A-and-B-Treatment.jpg https://thepharmadata.com/results-from-phase-3-talapro-2-trial-indicate-talzenna-and-xtandi-boost-overall-survival/ 2024-10-14T11:25:32+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Results-from-Phase-3-TALAPRO-2-Trial-Indicate-TALZENNA-and-XTANDI-Boost-Overall-Survival.webp https://thepharmadata.com/gilead-to-showcase-antiviral-portfolio-and-hiv-innovations-at-idweek-2024/ 2024-10-14T11:32:54+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Gilead-to-Showcase-Antiviral-Portfolio-and-HIV-Innovations-at-IDWeek-2024.webp https://thepharmadata.com/gilead-shares-new-efficacy-safety-and-demographic-data-from-purpose-2-trial-at-hiv-research-for-prevention-conference/ 2024-10-14T11:37:47+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Gilead-Shares-New-Efficacy-Safety-and-Demographic-Data-from-PURPOSE-2-Trial-at-HIV-Research-for-Prevention-Conference.jpg https://thepharmadata.com/empowering-the-veterinary-workforce-by-broadening-educational-access/ 2024-10-14T11:48:00+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Empowering-the-Veterinary-Workforce-by-Broadening-Educational-Access.webp https://thepharmadata.com/gsk-reports-positive-data-for-arexvy-rsv-vaccine-showing-protection-over-three-seasons/ 2024-10-14T11:57:55+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/GSK-Reports-Positive-Data-for-Arexvy-RSV-Vaccine-Showing-Protection-Over-Three-Seasons.webp https://thepharmadata.com/biogens-felzartamab-gains-fda-breakthrough-therapy-designation-for-kidney-transplant-rejection/ 2024-10-14T12:11:36+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Biogens-Felzartamab-Gains-FDA-Breakthrough-Therapy-Designation-for-Kidney-Transplant-Rejection.jpg https://thepharmadata.com/medic-life-sciences-partners-with-hanmi-on-cancer-biomarker-discovery-secures-strategic-investment/ 2024-10-15T10:06:08+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/MEDiC-Life-Sciences-Partners-with-Hanmi-on-Cancer-Biomarker-Discovery-Secures-Strategic-Investment.webp https://thepharmadata.com/supergut-expands-nationwide-at-target-amid-sales-surge/ 2024-10-15T10:24:40+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Supergut-Expands-Nationwide-at-Target-Amid-Sales-Surge.webp https://thepharmadata.com/bausch-lomb-gains-fda-approval-for-envista-envy-intraocular-lens-offering-full-range-of-vision/ 2024-10-15T10:41:04+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Bausch-Lomb-Gains-FDA-Approval-for-enVista-Envy-Intraocular-Lens-Offering-Full-Range-of-Vision.webp https://thepharmadata.com/fda-clears-spectralis-flex-module-enhancing-advanced-ophthalmic-imaging-for-underserved-patients/ 2024-10-15T10:51:18+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/FDA-Clears-SPECTRALIS-Flex-Module-Enhancing-Advanced-Ophthalmic-Imaging-for-Underserved-Patients.webp https://thepharmadata.com/lenovo-launches-first-ai-avatar-for-alzheimers-and-dementia-care/ 2024-10-16T10:26:37+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Lenovo-Launches-First-AI-Avatar-for-Alzheimers-and-Dementia-Care.webp https://thepharmadata.com/fda-approves-novocures-optune-lua-for-metastatic-non-small-cell-lung-cancer-treatment/ 2024-10-16T10:51:14+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/FDA-Approves-Novocures-Optune-Lua®-for-Metastatic-Non-Small-Cell-Lung-Cancer-Treatment.webp https://thepharmadata.com/urogen-announces-fda-acceptance-of-new-drug-application-for-ugn-102/ 2024-10-16T11:12:06+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/UroGen-Announces-FDA-Acceptance-of-New-Drug-Application-for-UGN-102.webp https://thepharmadata.com/anthem-blue-cross-and-open-table-launch-initiative-to-tackle-youth-substance-use-disorder/ 2024-10-16T11:39:07+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Anthem-Blue-Cross-and-Open-Table-Launch-Initiative-to-Tackle-Youth-Substance-Use-Disorder.webp https://thepharmadata.com/marinus-pharmaceuticals-expands-intellectual-property-with-new-patent-for-ztalmy-titration-methods/ 2024-10-16T11:53:42+05:30 https://thepharmadata.com/wp-content/uploads/2024/05/AstraZeneca-Announces-1.5-Billion-Facility-for-Antibody-Drug-Conjugates-ADCs-Manufacturing-in-Singapore.webp https://thepharmadata.com/bit-bio-secures-major-patent-victory-for-revolutionary-opti-ox-cell-programming-technology/ 2024-10-16T12:04:55+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/bit.bio-Secures-Major-Patent-Victory-for-Revolutionary-opti-ox™-Cell-Programming-Technology.webp https://thepharmadata.com/novotech-earns-prestigious-us-great-place-to-work-certification/ 2024-10-16T12:18:06+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Novotech-Earns-Prestigious-US-Great-Place-to-Work®-Certification.webp https://thepharmadata.com/lupin-introduces-first-generic-version-of-pred-forte-in-the-u-s/ 2024-10-16T14:49:40+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Lupin-Introduces-First-Generic-Version-of-Pred-Forte®-in-the-U.S-scaled.webp https://thepharmadata.com/elancos-parvovirus-antibody-boosts-puppy-survival-eases-vet-clinic-strain/ 2024-10-16T14:59:38+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Elancos-Parvovirus-Antibody-Boosts-Puppy-Survival-Eases-Vet-Clinic-Strain.webp https://thepharmadata.com/yemen-starts-sharing-seasonal-influenza-viruses-with-who-centre-in-london/ 2024-10-16T15:10:23+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Yemen-Starts-Sharing-Seasonal-Influenza-Viruses-with-WHO-Centre-in-London.webp https://thepharmadata.com/enhancing-biological-specimen-shipping-for-faster-disease-detection-and-response/ 2024-10-16T15:18:09+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Enhancing-Biological-Specimen-Shipping-for-Faster-Disease-Detection-and-Response.webp https://thepharmadata.com/attacks-on-hospitals-and-health-workers-threaten-healthcare-delivery-in-lebanon/ 2024-10-16T15:27:20+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Attacks-on-Hospitals-and-Health-Workers-Threaten-Healthcare-Delivery-in-Lebanon.webp https://thepharmadata.com/qatar-who-collaboration-sets-a-new-standard-for-safer-healthier-mega-sporting-events/ 2024-10-16T15:38:44+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Qatar-WHO-Collaboration-Sets-a-New-Standard-for-Safer-Healthier-Mega-Sporting-Events.webp https://thepharmadata.com/jazz-pharmaceuticals-reports-positive-survival-results-for-zepzelca-and-atezolizumab-in-lung-cancer/ 2024-10-16T15:53:12+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Jazz-Pharmaceuticals-Reports-Positive-Survival-Results-for-Zepzelca®-and-Atezolizumab-in-Lung-Cancer.webp https://thepharmadata.com/grifols-sets-record-with-highest-score-in-2024-sp-global-sustainability-assessment/ 2024-10-16T16:01:07+05:30 https://thepharmadata.com/wp-content/uploads/2024/07/Vertex-Announces-FDA-Acceptance-of-Suzetrigine-NDA-for-Acute-Pain_11zon.webp https://thepharmadata.com/rozebalamin-injection-for-als-wins-2024-good-design-award-for-lightproof-vial-packaging/ 2024-10-16T16:07:56+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/ROZEBALAMIN®-Injection-for-ALS-Wins-2024-Good-Design-Award-for-Lightproof-Vial-Packaging.webp https://thepharmadata.com/mary-kay-ash-foundation-awards-2-4m-to-combat-domestic-violence-and-womens-cancers/ 2024-10-16T17:21:49+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/pexels-pixabay-259027.webp https://thepharmadata.com/colossal-reaches-key-scientific-milestones-in-thylacine-de-extinction-efforts/ 2024-10-17T10:05:17+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Colossal-Reaches-Key-Scientific-Milestones-in-Thylacine-De-Extinction-Efforts.webp https://thepharmadata.com/careplus-unveils-2025-medicare-advantage-plan-options/ 2024-10-17T10:18:49+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/CarePlus-Unveils-2025-Medicare-Advantage-Plan-Options.webp https://thepharmadata.com/exscientia-reaches-key-milestones-in-two-programs-under-sanofi-collaboration/ 2024-10-17T10:27:19+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Exscientia-Reaches-Key-Milestones-in-Two-Programs-Under-Sanofi-Collaboration.webp https://thepharmadata.com/nielseniq-asia-pacific-consumer-outlook-2025-resilience-and-purposeful-consumption/ 2024-10-17T10:39:45+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/NielsenIQ-Asia-Pacific-Consumer-Outlook-2025-–-Resilience-and-Purposeful-Consumption.webp https://thepharmadata.com/innovative-lab-services-llc-purchases-mls-technologies-inc/ 2024-10-17T10:49:16+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Innovative-Lab-Services-LLC-Purchases-MLS-Technologies-Inc.webp https://thepharmadata.com/foodminds-launches-2024-global-report-on-conscious-consumption-index/ 2024-10-17T10:57:00+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/FoodMinds-Launches-2024-Global-Report-on-Conscious-Consumption-Index.webp https://thepharmadata.com/new-study-shows-significant-decline-in-life-expectancy-improvements/ 2024-10-17T11:07:42+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/New-Study-Shows-Significant-Decline-in-Life-Expectancy-Improvements.webp https://thepharmadata.com/horizon-surgical-systems-secures-30-million-in-series-a-funding/ 2024-10-17T11:15:54+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Horizon-Surgical-Systems-Secures-30-Million-in-Series-A-Funding.webp https://thepharmadata.com/verastem-oncology-highlights-ramp-201-data-for-avutometinib-and-defactinib-in-ovarian-cancer-at-igcs-2024/ 2024-10-17T11:26:30+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Verastem-Oncology-Highlights-RAMP-201-Data-for-Avutometinib-and-Defactinib-in-Ovarian-Cancer-at-IGCS-2024.webp https://thepharmadata.com/gensight-biologics-unveils-lumevoq-scientific-updates-at-aao-2024/ 2024-10-17T11:34:13+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/GenSight-Biologics-Unveils-LUMEVOQ®-Scientific-Updates-at-AAO-2024.webp https://thepharmadata.com/sensorion-to-present-gjb2-gt-at-european-society-of-gene-and-cell-therapy-congress/ 2024-10-17T11:43:34+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Sensorion-to-Present-GJB2-GT-at-European-Society-of-Gene-and-Cell-Therapy-Congress.webp https://thepharmadata.com/womans-brain-foundation-and-medscape-education-launch-centre-on-sex-gender-and-the-brain/ 2024-10-17T11:52:24+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Womans-Brain-Foundation-and-Medscape-Education-Launch-Centre-on-Sex-Gender-and-the-Brain.webp https://thepharmadata.com/bayer-to-showcase-new-research-on-menopause-symptoms-at-ims-2024/ 2024-10-17T12:21:07+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Bayer-to-Showcase-New-Research-on-Menopause-Symptoms-at-IMS-2024.webp https://thepharmadata.com/fda-grants-priority-review-for-gepotidacin-to-treat-uncomplicated-utis-in-women-and-adolescents/ 2024-10-17T12:30:44+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/FDA-Grants-Priority-Review-for-Gepotidacin-to-Treat-Uncomplicated-UTIs-in-Women-and-Adolescents.webp https://thepharmadata.com/viiv-healthcare-reports-over-99-effectiveness-for-apretude-in-real-world-studies-at-idweek-2024/ 2024-10-17T12:36:46+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/ViiV-Healthcare-Reports-Over-99-Effectiveness-for-Apretude-in-Real-World-Studies-at-IDWeek-2024.webp https://thepharmadata.com/mercks-capvaxive-vaccine-shows-positive-immune-response-in-adults-at-risk-for-pneumococcal-disease/ 2024-10-17T12:59:18+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Mercks-CAPVAXIVE™-Vaccine-Shows-Positive-Immune-Response-in-Adults-at-Risk-for-Pneumococcal-Disease.webp https://thepharmadata.com/etcembly-and-university-of-surrey-launch-study-on-next-gen-cancer-treatments-from-survivors/ 2024-10-17T14:10:24+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Etcembly-and-University-of-Surrey-Launch-Study-on-Next-Gen-Cancer-Treatments-from-Survivors.webp https://thepharmadata.com/astrazeneca-pushes-forward-infectious-disease-protection-science-at-idweek-2024/ 2024-10-17T14:21:05+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/AstraZeneca-Pushes-Forward-Infectious-Disease-Protection-Science-at-IDWeek-2024.webp https://thepharmadata.com/sanofi-and-orano-collaborate-to-advance-next-generation-radioligand-therapies/ 2024-10-17T14:30:41+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Radioligand-Therapies.webp https://thepharmadata.com/alnylam-submits-ema-application-for-vutrisiran-in-attr-amyloidosis-treatment/ 2024-10-17T14:53:14+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Alnylam-Submits-EMA-Application-for-Vutrisiran-in-ATTR-Amyloidosis-Treatment.webp https://thepharmadata.com/beigene-showcases-waldenstroms-macroglobulinemia-advances-at-iwwm-2024/ 2024-10-17T15:04:30+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/BeiGene-Showcases-Waldenstroms-Macroglobulinemia-Advances-at-IWWM-2024.webp https://thepharmadata.com/wuxi-biologics-earns-fourth-consecutive-esg-corporate-platinum-award-from-the-asset/ 2024-10-17T16:00:00+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/WuXi-Biologics-Earns-Fourth-Consecutive-ESG-Corporate-Platinum-Award-from-The-Asset.webp https://thepharmadata.com/shionogi-showcases-global-study-on-cefiderocol-highlighting-high-clinical-response-in-critically-ill-patients/ 2024-10-17T16:15:32+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Shionogi-Showcases-Global-Study-on-Cefiderocol-Highlighting-High-Clinical-Response-in-Critically-Ill-Patients.webp https://thepharmadata.com/regional-study-shows-blood-biomarkers-can-predict-brain-amyloid-beta-accumulation/ 2024-10-17T16:24:02+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Regional-Study-Shows-Blood-Biomarkers-Can-Predict-Brain-Amyloid-Beta-Accumulation.webp https://thepharmadata.com/viatris-secures-global-licensing-deal-with-lexicon-for-sotagliflozin-outside-u-s-and-europe/ 2024-10-17T16:30:45+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Viatris-Secures-Global-Licensing-Deal-with-Lexicon-for-Sotagliflozin-Outside-U.S.-and-Europe.webp https://thepharmadata.com/helfie-ai-adds-healthcare-experts-antonin-de-fougerolles-and-cheryl-buxton-to-board-of-directors/ 2024-10-18T09:54:07+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Helfie-AI-Adds-Healthcare-Experts-Antonin-de-Fougerolles-and-Cheryl-Buxton-to-Board-of-Directors.webp https://thepharmadata.com/amivas-unveils-europes-first-licensed-treatment-for-severe-malaria/ 2024-10-18T10:00:50+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/AMIVAS-Unveils-Europes-First-Licensed-Treatment-for-Severe-Malaria.webp https://thepharmadata.com/marinus-pharma-shares-phase-3-raise-trial-results-on-refractory-status-epilepticus-at-neurocritical-care-2024/ 2024-10-18T10:06:20+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Marinus-Pharma-Shares-Phase-3-RAISE-Trial-Results-on-Refractory-Status-Epilepticus-at-Neurocritical-Care-2024.webp https://thepharmadata.com/sage-therapeutics-restructures-to-prioritize-zurzuvae-launch-and-streamline-development-pipeline/ 2024-10-18T10:13:23+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Sage-Therapeutics-Restructures-to-Prioritize-ZURZUVAE®-Launch-and-Streamline-Development-Pipeline.webp https://thepharmadata.com/modivcare-and-tenovi-partner-to-improve-respiratory-care-with-hailie-smart-inhalers/ 2024-10-18T10:20:27+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Modivcare-and-Tenovi-Partner-to-Improve-Respiratory-Care-with-Hailie®-Smart-Inhalers.webp https://thepharmadata.com/minze-health-secures-5-3-million-to-advance-prescription-digital-therapeutics-and-u-s-market-commercialization/ 2024-10-18T10:28:41+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Minze-Health-Secures-5.3-Million-to-Advance-Prescription-Digital-Therapeutics-and-U.S.-Market-Commercialization.webp https://thepharmadata.com/iproov-sees-60-growth-in-transactions-amid-rising-demand-for-biometric-solutions/ 2024-10-18T10:38:10+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/iProov-Sees-60-Growth-in-Transactions-Amid-Rising-Demand-for-Biometric-Solutions.webp https://thepharmadata.com/eric-murphy-ph-d-ceo-of-alterome-named-goldman-sachs-top-100-entrepreneur-for-2024/ 2024-10-18T10:45:16+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Eric-Murphy-Ph.D.-CEO-of-Alterome-Named-Goldman-Sachs-Top-100-Entrepreneur-for-2024.webp https://thepharmadata.com/1910-genetics-launches-candid-cns-an-ai-model-surpassing-blood-brain-barrier-permeability-standards/ 2024-10-18T10:54:37+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/1910-Genetics-Launches-CANDID-CNS™-an-AI-Model-Surpassing-Blood-Brain-Barrier-Permeability-Standards.webp https://thepharmadata.com/charles-river-introduces-new-retrogenix-non-human-protein-library/ 2024-10-18T11:07:29+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Charles-River-Introduces-New-Retrogenix®-Non-Human-Protein-Library.webp https://thepharmadata.com/tasso-inc-survey-one-in-three-patients-delay-blood-tests-due-to-anxiety-and-pain/ 2024-10-18T11:14:26+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Tasso-Inc.-Survey-One-in-Three-Patients-Delay-Blood-Tests-Due-to-Anxiety-and-Pain.webp https://thepharmadata.com/ivi-rma-north-america-to-showcase-leading-infertility-research-at-asrm-2024/ 2024-10-18T11:19:25+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/IVI-RMA-North-America-to-Showcase-Leading-Infertility-Research-at-ASRM-2024.webp https://thepharmadata.com/transcarent-chosen-to-enhance-evernorths-comprehensive-cancer-care-experience/ 2024-10-18T11:26:16+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Transcarent-Chosen-to-Enhance-Evernorths-Comprehensive-Cancer-Care-Experience.webp https://thepharmadata.com/ge-healthcares-new-hospital-pulse-tile-secures-first-major-academic-medical-center-customer/ 2024-10-18T11:33:50+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/GE-HealthCares-New-Hospital-Pulse-Tile-Secures-First-Major-Academic-Medical-Center-Customer.webp https://thepharmadata.com/wisp-introduces-comprehensive-weight-care-program-for-women-facing-hormonal-imbalances/ 2024-10-18T11:38:49+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Wisp-Introduces-Comprehensive-Weight-Care-Program-for-Women-Facing-Hormonal-Imbalances.webp https://thepharmadata.com/nordic-group-launches-lacrifill-canalicular-gel-for-dry-eye-at-aao-2024/ 2024-10-18T11:44:37+05:30 https://thepharmadata.com/wp-content/uploads/2024/10/Nordic-Group-Launches-LACRIFILL®-Canalicular-Gel-for-Dry-Eye-at-AAO-2024.webp